These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 12538024)
21. Can beta-lactams be re-engineered to beat MRSA? Livermore DM Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():11-6. PubMed ID: 16524423 [TBL] [Abstract][Full Text] [Related]
22. Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action. Ono D; Yamaguchi T; Hamada M; Sonoda S; Sato A; Aoki K; Kajiwara C; Kimura S; Fujisaki M; Tojo H; Sasaki M; Murakami H; Kato K; Ishii Y; Tateda K J Infect Chemother; 2019 Apr; 25(4):273-280. PubMed ID: 30713034 [TBL] [Abstract][Full Text] [Related]
23. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus. Park YS; Shin WS; Kim SK J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. Sader HS; Farrell DJ; Flamm RK; Jones RN Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170 [TBL] [Abstract][Full Text] [Related]
29. Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Sader HS; Fritsche TR; Jones RN Antimicrob Agents Chemother; 2008 Mar; 52(3):1153-5. PubMed ID: 18180353 [TBL] [Abstract][Full Text] [Related]
30. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079 [TBL] [Abstract][Full Text] [Related]
31. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Dilworth TJ; Leonard SN; Vilay AM; Mercier RC Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667 [TBL] [Abstract][Full Text] [Related]
32. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380 [TBL] [Abstract][Full Text] [Related]
33. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161 [TBL] [Abstract][Full Text] [Related]
34. TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. Kaul M; Mark L; Zhang Y; Parhi AK; Lyu YL; Pawlak J; Saravolatz S; Saravolatz LD; Weinstein MP; LaVoie EJ; Pilch DS Antimicrob Agents Chemother; 2015 Aug; 59(8):4845-55. PubMed ID: 26033735 [TBL] [Abstract][Full Text] [Related]
35. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. Lepak AJ; Marchillo K; Craig WA; Andes DR Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404 [TBL] [Abstract][Full Text] [Related]
36. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program. Biedenbach DJ; Hoban DJ; Reiszner E; Lahiri SD; Alm RA; Sahm DF; Bouchillon SK; Ambler JE Antimicrob Agents Chemother; 2015 Dec; 59(12):7873-7. PubMed ID: 26416860 [TBL] [Abstract][Full Text] [Related]
37. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa. Shittu AO; Lin J BMC Infect Dis; 2006 Jul; 6():125. PubMed ID: 16875502 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents. Ling C; Fu L; Gao S; Chu W; Wang H; Huang Y; Chen X; Yang Y J Med Chem; 2014 Jun; 57(11):4772-95. PubMed ID: 24874438 [TBL] [Abstract][Full Text] [Related]
39. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review. Chang VS; Dhaliwal DK; Raju L; Kowalski RP Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722 [TBL] [Abstract][Full Text] [Related]
40. Improvement of water-soluble cephalosporin derivatives having antibacterial activity against methicillin-resistant Staphylococcus aureus. Hanaki H; Nomura S; Akagi H; Hiramatsu K Chemotherapy; 2001; 47(3):170-6. PubMed ID: 11306785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]